Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453384 | 0.90 | LMNA (0.64) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL4152901 | 0.84 | GRM1 (0.81) | ALDH1A1HPGDLMNAGRM1MAPT | |
| SCHEMBL12666730 | 0.83 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL13108851 | 0.80 | GRM1 (0.67) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL1006092 | 0.79 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL4132111 | 0.79 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL1009791 | 0.79 | AIP (0.52) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL3478613 | 0.79 | GRM1 (0.84) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL8226585 | 0.79 | GRM1 (0.68) | SMN1; SMN2ALDH1A1HPGDLMNAGRM1 | |
| SCHEMBL1898267 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1LMNAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041124-B1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | MSD OSS BV (NL) | 2013-06-26 | — | — | EP | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2041124-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. Organon (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255086-A1 | Heterocyclic Derivatives | GRIN2C, GRIN3A, GRIN1 | SMN1; SMN2 1870/4885ALDH1A1 453/4885HPGD 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.